Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

antitrust investigation

- PMLiVE

Lundbeck still feeling effects from Cipralex patent loss

The antidepressant sales dropped another 33% in the third quarter

EU flag

EC: medicines to remain part of health directorate

Juncker U-turns on decision to move pharma oversight to enterprise and industry

- PMLiVE

EMA draws fire on new clinical reports policy

Has recently come under pressure from transparency groups

- PMLiVE

NICE recommends Lundbeck’s alcohol dependency drug

NHS patients to have access to Selincro to help control drinking

- PMLiVE

Lundbeck launches Brintellix in first EU market

The antidepressant set to sell worldwide

EU flag

EC slammed for pharma oversight changes

Organisations criticise decision to transfer responsibility for pharma policy from health to industrial department

European Commissioner for health and food safety elected

Vytenis Andriukaitis will take on the role from October

- PMLiVE

Roche’s Avastin gets new EU nod in ovarian cancer

Wins new approval for hard-to-treat platinum-resistant recurrent form of disease

- PMLiVE

Otsuka and Lundbeck file Abilify follow-up in the US

Brexpiprazole to be reviewed for use in schizophrenia and major depressive disorder

- PMLiVE

EU hits Servier and generic firms with €428m ‘pay-for-delay’ fine

Follows deals to delay competition for blood pressure drug Coversyl/Aceon

- PMLiVE

NICE backs Lundbeck’s alcohol dependence drug Selincro

Alcoholics in England to have access to once-daily drug

- PMLiVE

Lundbeck’s desmoteplase flunks phase III stroke trial

No better than placebo at improving disability symptoms

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links